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Abstract
Background: Chronic Chagas disease presents several different clinical manifestations ranging from asymptomatic to severe
cardiac and/or digestive clinical forms. Several studies have demonstrated that immunoregulatory mechanisms are
important processes for the control of the intense immune activity observed in the chronic phase. T cells play a critical role
in parasite specific and non-specific immune response elicited by the host against Trypanosoma cruzi. Specifically, memory T
cells, which are basically classified as central and effector memory cells, might have a distinct migratory activity, role and
function during the human Chagas disease.
Methodology/Principal Findings: Based on the hypothesis that the disease severity in humans is correlated to the quality
of immune responses against T. cruzi, we evaluated the memory profile of peripheral CD4
+ and CD8
+ T lymphocytes as well
as its cytokine secretion before and after in vitro antigenic stimulation. We evaluated cellular response from non-infected
individuals (NI), patients with indeterminate (IND) or cardiac (CARD) clinical forms of Chagas disease. The expression of
CD45RA, CD45RO and CCR7 surface molecules was determined on CD4
+ and CD8
+ T lymphocytes; the pattern of
intracellular cytokines (IFN-c, IL-10) synthesized by naive and memory cells was determined by flow cytometry. Our results
revealed that IND and CARD patients have relatively lower percentages of naive (CD45RA
high) CD4
+ and CD8
+ T cells.
However, statistical analysis of ex-vivo profiles of CD4
+ T cells showed that IND have lower percentage of CD45RA
high in
relation to non-infected individuals, but not in relation to CARD. Elevated percentages of memory (CD45RO
high) CD4
+ T cells
were also demonstrated in infected individuals, although statistically significant differences were only observed between
IND and NI groups. Furthermore, when we analyzed the profile of secreted cytokines, we observed that CARD patients
presented a significantly higher percentage of CD8
+CD45RA
high IFN-c-producing cells in control cultures and after antigen
pulsing with soluble epimastigote antigens.
Conclusions: Based on a correlation between the frequency of IFN-c producing CD8+ T cells in the T cell memory
compartment and the chronic chagasic myocarditis, we propose that memory T cells can be involved in the induction of the
development of the severe clinical forms of the Chagas disease by mechanisms modulated by IFN-c. Furthermore, we
showed that individuals from IND group presented more TCM CD4
+ T cells, which may induce a regulatory mechanism to
protect the host against the exacerbated inflammatory response elicited by the infection.
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Introduction
Infection with the protozoan Trypanosoma cruzi is a major cause of
morbidity and mortality in Central and South America, accounting
for 12.500 deaths per year [1,2]. The acute phase of infection is
characterized by intense and evident blood parasitemia and may
result in death. Upon infection, both the innate and adaptive
immune responses lead to the control of parasite levels in the acute
phase of the infection, but are insufficient for complete clearance of
the T. cruzi. However, this phase is generally followed by an
asymptomatic or indeterminate phase, during which there are no
clinical symptoms or clear evidence of the presence of the parasite.
The asymptomatic phase may last months to decades. Thus, most
individuals are infected for life, with parasites persisting primarily in
muscle cells, and approximately 30% of the individuals developing
cardiac clinical form of Chagas disease [3,4].
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latent period that precedes morbidity, and the intriguing existence
of different clinical forms as well as a clear involvement of the
immune response, have led several authors to evaluate the
involvement of auto-immune factors in the pathogenesis of the
disease. Some authors have pointed out the existence of cross-
reactions between host tissues and T. cruzi antigens [5–14].
However, the demonstration of the presence of T. cruzi or its
antigens by immunohistochemical techniques or of T. cruzi DNA
by polymerase chain reaction (PCR) in inflamed myocardial
tissues suggest that parasite antigens may be necessary to trigger
the inflammatory process [15–17]. Therefore, both processes may
be involved on the development of the severe clinical forms of the
disease and may act synergistically as the disease progresses.
Although a significant percentage of the patients will develop
the severe forms of the disease, a larger proportion remains
asymptomatic throughout life. These observations have stimulated
several investigators to study the processes involved on the
development of severe pathology as well as on the maintenance
of the asymptomatic forms of Chagas disease. In fact, many studies
have demonstrated that immunoregulatory mechanisms are
important for the control of infection, possibly affecting disease
morbidity in chronic clinical forms [18–20]. We have recently
observed that patients with the indeterminate (IND) clinical form
of chronic Chagas disease have higher percentages of
CD4
+CD25
high T cell population secreting IL-10 expressing
FOXP3 [18]. These data suggest that an increase in the secretion
of IL-10 by regulatory T cells during the chronic phase of the
disease may be associated with protection of the host against the
severe pathology induced by type 1 immune response [18,21,22].
Immunity to T. cruzi is complex, minimally involving a
substantial antibody response and the activation of appropriate
CD4
+ and CD8
+ T cell responses. The role of CD8
+ and CD4
+ T
lymphocytes in resistance to T. cruzi and in the severity of clinical
disease remains unclear. In our laboratory, we have previously
demonstrated that patients with the cardiac clinical form (CARD)
of chronic Chagas disease elicit a robust immune response against
the parasite, with high levels of IFN-c and low levels of IL-10
[21,22] and that this response is associated with severe cardiac
pathology. Similarly, Abel et al. suggests that the ability to mount a
vigorous IFN-c-response may be associated with the development
of cardiomyopathy [23]. However, Laucella et al. showed that
patients with mild disease display substantial amounts of IFN-c-
producing T cells, suggesting that severe disease is prevented,
rather than caused, by an immune response dominated by type-1
cytokine production [24]. Additionally, Garg and Tarleton
demonstrated that enhancing type 1 immune responses through
genetic immunization can substantially reduce the severity of
disease in persistently infected mice (Garg and Tarleton, 2002).
Heterogeneity of the response is a hallmark of antigen-specific T
cells. CD4
+ T cells may develop into T helper cell 1 (TH1), TH2,
or TH17 cells and likewise become antigen-specific regulatory cells
[25–27]. According to the model proposed by Lanzavecchia and
Sallusto [28], protective memory is mediated by effector memory
T cells (TEM) that migrate to inflamed peripheral tissues and
display immediate effector function, whereas reactive memory cell
development is mediated by central memory T cells (TCM) that
home to T cell areas of secondary lymphoid organs, have little or
no effector function, but readily proliferate and differentiate into
effector cells in response to antigenic stimulation. In fact, human
TCM are CD45RO memory cells that constitutively express CCR7
and CD62L, two receptors that are also characteristic of naive T
cells, which are required for cell extravasation through high
endothelial venules and migration to lymphoid organs [29–31].
Differently, human TEM are memory cells that have lost the
constitutive expression of CCR7, are heterogeneous for CD62L
expression, and display characteristic sets of chemokine receptors
and adhesion molecules that are required for homing to inflamed
tissues [31].
In addition to the repertoire of cytokine secretion, effector CD4
+
T cells exhibit diversity in the homing process, such as migration to
peripheral nonlymphoid tissue and transit to lymph node follicles
[32]. Furthermore, heterogeneity of CD8
+ T cell effector gene
expression has also been described [33], although it is not clear
whether this represents physiologically distinct cell fates or simply
fluctuation in activation state. Memory T cells are heterogeneous,
with central memory cells patrolling secondary lymphoid tissues,
recapitulating the surveillance of their naive progenitor, and effector
memory cells acting as sentinels at frontline barriers [34]. Although
the roleand function of effector and memorysubsets inprotection or
pathology and the nature of polarizing signals required for their
differentiation are becoming increasingly clear, there are still
outstanding questions that need to be addressed, which are mainly
related to the mechanism of T cell fate. Many of these questions deal
with fundamental uncertainties that are common to many areas of
blood cell differentiation, such as the extent of fate diversity, the
ontogeny and lineage relationship between opposing and kindred
fates, and the degree of natural and therapeutic plasticity at different
stages of differentiation. In the experimental mouse model, Martin
and Tarleton [35] observed that antigen-specific CD4
+ and CD8
+ T
cells maintain a TEM phenotype during persistent T. cruzi infection.
Interestingly,itwas observedthatTCM CD8
+ memoryT cells can be
generated and maintained despite pathogen persistence in T. cruzi
infection. Furthermore, it was demonstrated that complete pathogen
clearancethroughbenzonidazoletreatmentresultsinstable,antigen-
independent and protective T cell memory, despite the potentially
exhausting effects of prior long-term exposure to antigen in chronic
infection [36,37]. On the other hand, Tzelepis and colleagues [38]
showed that the differentiation and expansion of T. cruzi-specific
CD8
+ cytotoxic T cells (TEM T cells) is dependent on parasite
multiplication. In humans, an increase in total effector/memory
CD8
+ T cells (CD45RA
2CCR7
2) was observed in CARD patients
Author Summary
Chagas disease is a parasitic infection caused by protozoan
Trypanosoma cruzi that affects approximately 11 million
people in Latin America. The involvement of the host’s
immune response on the development of severe forms of
Chagas disease has not been fully elucidated. Studies on
the immune response against T. cruzi infection show that
the immunoregulatory mechanisms are necessary to
prevent the deleterious effect of excessive immune
response stimulation and consequently the fatal outcome
of the disease. A recall response against parasite antigens
observed in in vitro peripheral blood cell culture clearly
demonstrates that memory response is generated during
infection. Memory T cells are heterogeneous and differ in
both the ability to migrate and exert their effector
function. This heterogeneity is reflected in the definition
of central (TCM) and effector memory (TEM) T cells. Our
results suggest that a balance between regulatory and
effectors T cells may be important for the progression and
development of the disease. Furthermore, the high
percentage of central memory CD4
+ T cells in indetermi-
nate patients after stimulation suggests that these cells
may modulate host’s inflammatory response by controlling
cell migration to tissues and their effector role during
chronic phase of the disease.
Memory T Cell Subtypes in Human Chagas Disease
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completely understood in human Chagas disease. In the present
study, we evaluated the profile of peripheral blood subsets of CD4
+
and CD8
+ T cells expressing naive/memorymarkers (CD45RA
high/
RO
high), memory cell subtypes (TCM2CD45RO
highCCR7
+ and
TEM2 CD45RO
highCCR7
2) and production of cytokines by
peripheral blood cells after in vitro stimulation with T. cruzi antigens
to evaluate a possible relationship between the presence of these cells
and the development of different clinical forms of the disease.
Materials and Methods
Recruitment of subjects
The initial cohort of study subjects was recruited 8 years ago at
the Outpatient Referral Center for Chagas Disease of the Hospital
das Clı ´nicas, Federal University of Minas Gerais, Brazil. All study
participants provided a written informed consent following the
guidelines of the Ethics Committee of the Federal University of
Minas Gerais. The study protocol complied with the regulations of
the Brazilian National Council on Research in Humans and was
approved by the Ethics Committee of the Federal University of
Minas Gerais under the protocol COEP/UFMG-372/04. Indi-
viduals with systemic arterial hypertension, diabetes mellitus, thyroid
dysfunction, renal insufficiency, chronic obstructive pulmonary
disease, hydroelectrolytic disorders, alcoholism, previous clinical
history suggesting coronary artery obstruction and rheumatic
disease, or who were unable to fulfill the study requirements for
annual examinations were excluded from the study. Individuals
were considered seropositive for T. cruzi infection if two or more of
the standard tests performed, indirect immunofluorescence,
ELISA or indirect haemagglutination, were positive. Study
participants were evaluated annually for a range of clinical and
immunological parameters related to Chagas disease [22].
In this study, we investigated the immune response of 23
patients, who fulfilled the protocol described above, all in the
chronic phase of the infection. The patients infected with T. cruzi
were classified as being in the indeterminate phase of Chagas
(IND) or having the cardiac (CARD) form of the disease as
previously reported [18]. Individuals in the IND group (n=9)
ranged from 30 to 68 years of age. These individuals had no
significant alterations in the electrocardiography, chest x-ray,
echocardiogram, esophagogram and barium enema. The CARD
group age (n=14) ranged from 29 to 73 years, and presented
echocardiographic and/or clinical and radiological signs of heart
enlargement, with a final diastolic diameter of the left ventricle
greater than 55 mm. The cardiac patients that participated in this
study were classified as belonging to the group CARD V, as
previously reported [18]. Twelve healthy individuals, 29 to 61
years old, from a non-endemic area for Chagas disease, and who
had negative serology for Chagas disease, were included in the
control group (NI).
Antigens
Epimastigote (EPI) antigens wereprepared by usingthe CL strain
of T. cruzi as previously described [18,21,22]. Briefly, EPI were
washed three times in cold phosphate-buffered saline (PBS),
disrupted by repeated freezing at 270uC and thawing, homoge-
nized at 4 to 6uC in a Potter-Elvejem (Vir Tis-Precise Wisconsin,
USA) and centrifuged at 20,0006g five times at 4uC for 60 seconds,
with 30 seconds intervals. The suspension was subsequently
centrifuged at 40,0006g for 60 minutes in the cold. The clear
supernatant was dialyzed for 24 hours at 4uC against PBS, filter
sterilized on 0.22-mm pore-size membranes, assayed for protein
concentration, aliquoted, and stored at 270uC until needed.
Flow cytometric analysis of peripheral blood
WholebloodwascollectedinVacutainertubescontaining EDTA
(Becton Dickinson, USA) and 100 mL samples were mixed in tubes
with 2 mL of undiluted monoclonal antibodies conjugated with
fluorescein isothiocyanate (FITC), phycoerythrin (PE), R-phycoer-
ythrin coupled to the cyanine dye Cy5
TM (PE Cy5) or allophyco-
cyanin(APC) for the following cell surface markers: CD4 (RPA-T4),
CD8 (RPA-T8), CD62L (DREG56), CD45RA (HI100), CD45RO
(UCHL-1), CCR7 (3D12) (all from BD Pharmingen, USA). After
adding the antibodies, the cells were incubated in the dark for
30 minutes at room temperature.
Following incubation, erythrocytes were lysed using 2 mL of
FACS Lysing Solution (BD Biosciences, USA) and washed twice
with 2 mL of phosphate-buffered saline containing 0.01% sodium
azide. The cells were then fixed in formaldehyde (4%) and
permeabilized with saponin buffer (0.5%) (SIGMA, USA) for
15 minutes. After incubation, the cells were fixed in 200 mLo f
fixative solution (10 g/L paraformaldehyde, 1% sodium-cacodyl-
ate, 6.65 g/L sodium chloride, 0.01% sodium azide). Phenotypic
analyses were performed by flow cytometry with a FACScalibur
flow cytometer (BD Biosciences, USA). Data were collected on
1610
5 lymphocytes (gated by forward and side scatter) and
analyzed using CellQuest software (BD Biosciences, USA).
Flow cytometric analysis of cells culture
Whole blood was stimulated in vitro with EPI (25 mg/mL)
antigens in RPMI 1640 media supplemented with 1.6% L-
glutamine, 3% antibiotic-antimycotic, 5% of AB Rh-positive heat
inactivated normal human serum, for 22 hours at 37uC and 5%
CO2. Control cultures were maintained in culture media for the
same period of time. During the last 4 hours of culture, Brefeldin
A (SIGMA, St. Louis, MO, USA) (10 mg/mL) was added to the
cultures [18]. Cultured cells were washed twice in PBS containing
1% bovine serum albumin and stained with monoclonal
antibodies specific for the different cell-surface markers, as
described above. The cells were then fixed in formaldehyde (4%)
and permeabilized in saponin buffer (0.5%) for 15 minutes.
Finally, the cells were incubated with monoclonal antibodies
reactive to IL-10 (JES3-9D7) and IFN-c (B27) (both from BD
Pharmingen, USA). Phenotypic analyses were performed in a
FACScalibur flow cytometer (BD Biosciences, USA), and data
collected on 1610
5 lymphocytes and analyzed using the CellQuest
software (BD Biosciences, USA).
FACS analysis of surface markers and intracellular
cytokine
Lymphocytes were analyzed for their intracellular cytokine
expression patterns and frequencies as well as for cell surface markers
using Cell Quest software. The frequency of cells was analyzed in
four gates for each staining procedure: gate 1 (R1), lymphocyte gate
(Suplementary Figure S1A); gate R2, T CD4
+ and CD8
+ expressing
CD45RA
high and CD45RO
high lymphocytes (Suplementary Figure
S1B) ; gate R3, T CD4
+ and CD8
+ lymphocytes (Suplementary
Figure S1C); gate R4, T CD4
+ and CD8
+ lymphocytes expressing
CD45RO
high/CCR7
+(SuplementaryFigureS1D);gateR5,TCD4
+
and CD8
+ CD45RA
high/CD45RO
high lymphocytes secreting IFN-c
and IL-10 (Suplementary Figure S1E). Limits for the quadrant
markers were always set based on negative populations and isotype
controls.
Statistical analysis
Analyses were performed using GraphPad Prism version 4.0
software (GraphPad Software Inc, USA). The nonparametric tests
Memory T Cell Subtypes in Human Chagas Disease
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(NI6IND6CARD), followed by Dunns test to compare all pairs of
columns. Mann-Whitney nonparametric test was used to evaluate
the significance of the cytokine production and compare the pairs
of columns (NI6IND) (NI6CARD) (IND6CARD), comparing all
Differences were considered significant when a p value of less than
0.05 was obtained.
Results
Individuals with the indeterminate form of Chagas
disease have lower percentage of CD4
+ and CD8
+ naive
(CD45RA
high) and elevated percentages of memory
(CD45RO
high) T cells
The results show that the expression of CD45RA
high in CD4
+ T
cells, molecule expressed by naive T cells, was significantly lower
(p,0.05) in IND patients when compared to NI individuals ex vivo
(Figure 1A). We did not observe a significant difference between
the infected groups when evaluated ex vivo. Furthermore, the
percentage of CD8
+CD45RA
high T cells in CARD patients, after
culture in the absence of EPI antigens, was significantly lower
(p,0.05) when compared to NI individuals (Figure 1B). Similarly,
IND and CARD patients had a significantly lower percentage of
CD8
+CD45RA
high T cells, p,0.05 and p,0.01 respectively,
when compared to NI individuals in in vitro cultures in the presence
of EPI antigens (Figure 1B).
Our results also showed that the expression of CD45RO
high by
CD4
+ T cells, (memory lymphocytes), was not statistically different
between NI, IND and CARD groups ex vivo and in culture of
whole blood in the absence and presence of EPI antigens
(Figure 1C and D). However, the percentage of CD45RO
high
CD4
+ T cells in the IND group was significantly higher (p,0.05)
than in the NI group after culture without antigen stimulation
(Figure 1C).
When we evaluated the expression of CD45RO
high by CD8
+ T
cells, the data did not reveal statistically significant differences
between NI, IND and CARD groups, both ex vivo and in control
cultures (Figure 1D). However, the CARD group showed a
tendency to have higher percentages of these cells ex vivo when
compared to the other groups (Figure 1D). Note worthy, after in
vitro culture in the presence or not of EPI antigens, CARD patients
presented a decrease in the percentage of these cells (Figure 1D).
Chronic patients have an elevated percentage of T cells
secreting cytokines
The presence of intracytoplasmatic cytokines IFN-c and IL-10
in CD4
+ and CD8
+ T lymphocytes expressing either CD45RA
high
or CD45RO
high surface markers was evaluated in NI, IND and
Figure 1. Naive and memory T cells. Percentage of CD4
+ and CD8
+ T cells, evaluated by flow cytometry before and after a short in vitro
stimulation with T.cruzi antigen (EPI) as described in Material and Methods. A and B) CD45RA
high expression. C and D) CD45RO
high expression.
Ex vivo=before stimulation, CC=culture non estimulated and EPI=culture after stimulation. The differences between the groups are considered
significant at p less than 0.05 and are represented by * p,0.05, **p,0.01 and ***p,0.001.
doi:10.1371/journal.pntd.0000512.g001
Memory T Cell Subtypes in Human Chagas Disease
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EPI crude extract.
The data showed that CARD patients presented a significantly
higher percentage (p,0.01 and p,0,001) of CD8
+CD45RA
high
IFN-c-producing cells in control cultures (absence of antigen
stimulation) when compared to IND patients and NI individuals.
This percentage was also significantly higher in CARD group than
in NI individuals (p,0.01) after antigen pulsing with EPI
(Figure 2A). No significant differences were observed when we
evaluated the percentage of CD8
+CD45RA
high cells producing
IL-10 in cultures in the absence or presence of EPI antigens (data
not shown).
Data analysis revealed a significant increase (p,0.01) of IFN-c
+
CD4
+CD45RO
high cells in whole blood samples from chagasic
patients in comparison to NI individuals, after culture in the
presence of EPI antigens (Figure 2B). There were no statistically
significant differences among all studied groups evaluated after
culture in the absence of antigenic stimulation (Figure 2B).
Analysis of IL-10
+ CD4
+CD45RO
high T cells showed a
significant higher (p,0.05) percentage of these cells in CARD
Figure 2. Cytokines secreted by naive and memory T cells. Percentage of CD8
+CD45RA
high, CD4
+CD45RO
high and CD8
+CD45RO
high T cells,
evaluated by flow cytometry after a short in vitro stimulation without or with T.cruzi antigen (EPI) as described in Material and Methods. A and B)
Intracellular cytokine IFN-c expression. C) Intracellular cytokine IL-10 expression. CC=culture non estimulated and EPI=culture after stimulation. The
differences between the groups are considered significant at p less than 0.05 and are represented by * p,0.05, **p,0.01 and ***p,0.001.
doi:10.1371/journal.pntd.0000512.g002
Memory T Cell Subtypes in Human Chagas Disease
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absence of antigenic stimulation (Figure 2C). The results showed
that there is a significantly higher percentage of CD4
+CD45RO
high
T lymphocytes secreting IL-10 in CARD and IND patients
(p,0.001 and p,0.01, respectively), after culture in the presence
of antigens of EPI, when compared to NI group (Figure 2C).
Data analysis of the expression of cytokines IFN-c and IL-10 by
CD8
+CD45RO
high T cells did not show any significant difference
between the groups, after in vitro culture (data not shown).
Identification of human CD4
+ and CD8
+ T cell memory
subsets
Triple labeling of CD4
+ and CD8
+ T lymphocytes from
peripheral blood with the molecules CD45RA, CD45RO and
CCR7 allowed us to evaluate the process of recirculation of
lymphocytes (percentage of cells migrating to/from secondary
lymphoid organs).
We classified human CD4
+ and CD8
+ T cells by using two
markers, CD45RO and CCR7. Three-color flow cytometry analysis
demonstrated two major populations of human CD4
+ and CD8
+ T
cells, i.e. CCR7
+CD45RO
high and CCR7
2CD45RO
high.
The assessment of the percentage of CD4
+CD45RO
highCCR7
+
T cells demonstrated that CARD patients have significantly lower
percentage (p,0.05) of this sub-population ex vivo when compared
to NI individuals (Figure 3A). There were no significant differences
in the analysis of these cells after culture (Figure 3A). In the
analysis of CD4
+ cells CD45RO
highCCR7
2, we did not find any
differences on the percentage of cells between the groups, before
or after stimulation (Figure 3B).
The expression of the CD45RO
highCCR7
+ phenotype by CD8
+
cells, IND and CARD groups showed a significantly higher
percentage of these cells (p,0.05 and p,0.001) in comparison to
NI individuals in ex vivo (Figure 3A). The evaluation of these cells
after culture did not show any statistically significant differences
between the studied groups. (Figure 3A). When the percentage of
CD8
+CD45RO
highCCR7
2 T cells was assessed, we observed that
CARD group presented a higher percentage (p,0.05) than the
IND group ex vivo. A decrease on this percentage of this cell
population was demonstrated after in vitro culture (Figure 3B).
However, it was not statistically significant.
Discussion
Most mature peripheral T cells are at rest and can be divided
into naive and memory cells. This division is based on their
response to antigens in a secondary response [40]. In addition to
the functional activity, several markers have been identified to
allow the distinction of these cell populations. Naive T cells, which
Figure 3. Analyses of central and effector memory T cells. Percentage of CD45RO
highCCR7
+ CD4
+ and CD8
+ T cells, evaluated by flow
cytometry before and after a short in vitro stimulation with T.cruzi antigens (EPI) as described in Material and Methods. A) CD45RO
highCCR7
+
expression (TCM). B) CD45RO
highCCR7
2 expression (TEM). Ex vivo=before stimulation, CC=culture non estimulated and EPI=culture after stimulation.
The differences between the groups are considered significant at p less than 0.05 and are represented by * p,0.05, **p,0.01 and ***p,0.001.
doi:10.1371/journal.pntd.0000512.g003
Memory T Cell Subtypes in Human Chagas Disease
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and L-selectin on its surface, and do not express activation markers
such as CD25, CD44 and CD69 [40]. In contrast, memory T cells,
which were previously stimulated by an antigen, express high
levels of CD45RO and low levels of L-selectin [41]. In this study,
we demonstrate that IND and CARD patients have less naive
CD4
+ and CD8
+ T cells, demonstrated by decreased expression of
CD45RA, as well as lower levels of CD8
+ memory T cells when
compared to NI (control) individuals. Similar results have been
demonstrated by other study, in which patients in the chronic
phase of Chagas disease presented the same expression profile of
CD45RA
low in both CD4
+ and CD8
+ peripheral T cells [42].
Moreover, using an experimental model, another study demon-
strated that splenic CD8
+ T cells from T. cruzi-infected animals
show lower expression of CD45RA than cells from non-infected
mice [43]. The reduction of naive and increase of memory T cells
may occur during the chronic phase of the disease. This might
indicate a clonal T cell exhaustion due to continuous antigenic
stimulation by persistent parasites, and may be associated with
increased disease severity [42,44–46]. The reduction in the
expression of CD45RA is a direct result of the exchange of the
CD45 isoform from A to C, possibly leading to an easier
association with the TCR complex [47,48]. The C isoform allows
the cell to be activated by lower antigen stimulation and co-
stimulation [49]. The evaluation of CD4
+ T cells expressing
CD45RO
high showed a higher percentage of these cells in IND
group when compared to NI individuals after culture without
antigenic stimulation. In fact, several studies have shown that
altering the combination of CD45 isoforms dramatically affects
immune function and disease severity in autoimmune models.
Available data also show that this mechanism is related to an
altered threshold for TCR signaling, altered cytokine production
and response. This indicates that manipulating the patterns of
CD45 expression or signaling pathways that it modulates might be
a potential immunoregulatory strategy [47,48,50–52].
The mechanisms involved on the development of different
clinical forms of Chagas disease are still poorly understood,
suggesting that multiplefactors maybe involved initsestablishment,
such as cytokine production and profile of activation or differen-
tiation status defined by subsets of memory [53]. The most studied
cytokines in Chagas disease are IFN-c and IL-10. Several studies
have described some of the main cell populations involved in the
production of these cytokines, and their relationship with pathology
or regulation of immune responses during this infection
[18,22,23,54–60]. Our previous studies suggest a dual role for
IFN-c during human Chagas disease, which is observed during the
different stages of the infection (acute and chronic phases) or in the
presence or absence of treatment [22,54]. It has been shown that
during the acute phase of experimental mouse infection, IFN-c
participates in the elimination the parasite [55]. Furthermore, the
protective role of IFN-c has also been postulated in humans, as
individuals submitted to treatment show a strong cellular response
with secretion of high levels of this cytokine after in vitro stimulation
of PBMC [54]. On the other hand, studies on human chronic
Chagas disease have also shown that IFN-c production may be
harmful to the organism, since its unregulated production in the
heart tissue may promote the destruction of the myocardium due to
its cytotoxic effects. [23,54,61]. However, Laucella et al. showed a
linkage between increased T. cruzi-specific T cell-mediated IFN-c
responses and decreased disease severity. [24]. Indeed, there are
several important differences between all these studies, which might
contributeto discrepancies ininterpretation. Therefore,a long-term
immunological follow-up of T. cruzi-infected patients may provide
valuable information on the real role and contribution of IFN-c
responsestoparasitecontroland diseasedevelopment.Inthispaper,
we evaluate the secretion of IFN-c and IL-10 by CD4
+ and CD8
+
naive (CD45RA
high) and memory (CD45RO
high) T cells. We
observed that the subjects from the CARD group presented higher
percentage of naive CD8
+ T cells secreting IFN-c. This result
suggests that naive CD8
+ T cells might be associated with the
development of the cardiac clinical form of the disease, probably as
activated cells. Bourreau et al. [62], when evaluating the immune
response of PBMCs from the NI individuals after in vitro stimulation
with L. guyanensis antigens, demonstrated that CD8
+CD45RA
+ T
cells producing IFN-c are CD62L
2CCR7
2, while those producing
IL-10 are CD4
+CD45RA
+CCR7
2CD62L
+ T cells, which are
migrating to the inflammatory foci but are not yet activated. Our
group has also shown that in Chagas disease, patients from CARD
group develop a strong response against T.cruzi antigens, presenting
high levels of IFN-c and low levels of IL-10 [22]. Interestingly, here
we observed that chronic patients have more CD4
+CD45RO
high T
cells secreting both IFN-c and IL-10. Similarly, Antonelli et al.
(2004) [63] demonstrated that PBMC from patients infected with L.
braziliensis show high frequencies of memory CD4
+ T cells
producing both inflammatory (IFN-c) and regulatory (IL-10)
cytokines. This result suggests that these cells may not be the main
source of these cytokines, since they are producing both IL-10 and
IFN-c cytokines. Therefore, they may not be so relevant on the
development of the inflammatory process caused by protozoan
infections.
Moreover, some studies have shown that memory T cells may
be involved in the protection and development of Chagas disease
[35–37,39]. Nonetheless, a detailed evaluation of the cell
populations involved in recall responses in human Chagas disease
is still necessary. Memory T cells can be divided into two sub-
populations, based on their heterogeneity, effector functions and
response to the antigen or cytokines. Once activated, a fraction of
primed T lymphocytes persists as circulating memory cells that can
lead to protection and, upon secondary challenge, result in a
qualitatively different and quantitatively enhanced response
[31,64–68]. The central memory (TCM) human T cells express
CD45RO and also CCR7 and CD62L molecules, two important
receptors related to the migration of T cells to peripheral lymphoid
organs [30,69]. When compared to naive T cells, TCM have higher
sensitivity to antigen stimulation, are less dependent on co-
stimulation and provide efficient feedback for stimulation of
dendritic and B cells. After evaluation of memory subtypes, we
observed that chronic patients have more CD4
+ and CD8
+ TCM
cells ex vivo. However, after stimulation with EPI antigens, only the
IND group showed more TCM CD4
+ T cells. These data suggest
that when the overall T cell compartment is eventually driven to
exhaustion, it exhibits a low frequency of competent parasite-
specific CD8
+ T cells and predisposes the subject for disease
progression; this profile is presented by CARD patients with
persistence of antigens or re-infection by T. cruzi. Recently, using
the mouse model of T. cruzi infection, an increase in CD8
+ TCM
cells was observed during long-term persistent infection [36]. Of
note, these CD8
+ TCM cells were capable of antigen-independent
survival after being transferred into naive mice, and were
maintained despite the presence of persistent antigen stimulation.
Similarly, Bustamante et al. documented the development of
stable, antigen-independent CD8
+ T cell memory after benzoni-
dazole-induced cure of chronic infected mice [37].
It has been shown in mice that antigen-specific T cells maintain
an effector memory phenotype (TEM CD8
+ Tc e l l s )d u r i n gp e r s i s t e n t
T. cruzi infection [35,38], suggesting that these cells may play an
important role in the pathogenesis of the Chagas disease. However,
the process of cell development and differentiation from naive into
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infected with HIV (human immunodeficiency virus) or LCMV
(lymphocytic choriomeningitis virus) suggested that T cells go
through the process of differentiation from naiveRTCMRTEM
[70,71]. On the other hand, several authors suggest that the TCM
and TEM cells are actually independent subpopulations which
develop according to the biological environment, (eg.: presence of
different cytokines or the anatomical region of activation) are
independently maintained [71–73]. Finally, other studies on the
infection LCMV TCM show that the cells proliferate and/or convert
into TEM after re-exposure to the antigen, suggesting an alternative
model of CD8
+ T cell differentiation: naiveRTEMRTCM [74].
However, our data suggest that the type of differentiation is
naiveRTCMRTEM [70,75]. In fact, IND patients seem to have
some regulation that prevents TCM cells from becoming TEM,b u t
further studies are still needed to elucidate this question. Previous
studies have attempted to clarify the role of different subtypes of
memory cells using the experimental mouse model and the
CD45RA as a cell marker [39,76]. In the current study, we
evaluated the memory profile using CD45RO
highCCR7
+ phenotype
as a marker for TCM and CD45RO
highCCR7
2 for TEM Tc e l l s .
In conclusion, our results showed that CARD patients have
more naive CD8
+ T cells secreting IFN-c and TEM CD8
+ T cells
than IND and NI groups. Based on a correlation between the
frequency of IFN-c producing CD8
+ T cells in the T cell memory
compartment and the chronic chagasic myocarditis, we propose
that memory T cells might be involved in the induction of the
development of the severe clinical forms of the Chagas disease by
mechanisms modulated by IFN-c. Conversely, some authors have
demonstrated that high levels of IFN-c are inversely correlated
with disease severity [24,39]. In this way, the role of IFN-c in
human Chagas disease progression is not clear and should be
further elucidated by large follow-up studies. Moreover, we
demonstrated that individuals from IND group presented higher
levels of TCM CD4
+ T cells, which could induce immunoregula-
tory mechanisms to protect the host against the exacerbated
inflammatory response elicited by T. cruzi infection. Studies of
subtypes of immunological memory are still important for
understanding the role of these cells in Chagas disease (immmu-
noregulatory or pathogenic). Therefore, additional longitudinal
studies of changes in CD8
+ T cell sub-populations in chronically
infected subjects may reveal specific markers for progression to
severe disease.
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CD4
+ (R3). (D) Dot plot of FL-46FL-2, displaying the frequency of
CD4
+CD45RO
highCCR7
+ (UR). (E) Dot plot of FL-46FL-2,
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